Dr. Pierre Laneuville CML Chronic Myeloid Leukemia
Dr. Pierre Laneuville is an Associate Professor in the Department of Medicine and Oncology at McGill University and the former Head of Hematology for the McGill University Health Center. He is best known for his research on the molecular mechanisms underlying the genesis and transformation of chronic myelogenous leukemia.
VIDEOS
A look at where cancer research is today
February 4, 2023, CTV News
PCR and monitoring CML , ( Introduction PCR and monitoring CML Conclusion )
June 24, 2010, CML Society of Canada
A look at where cancer research is today
February 4, 2023, CTV News
PCR and monitoring CML , ( Introduction PCR and monitoring CML Conclusion )
June 24, 2010, CML Society of Canada
ARTICLES
More than $19 million for sustainable genomic solutions in human health and agrifood in Québec
May 30, 2024, Génome Québec
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Thrilled parents of MUHC’s first baby of 2019 boost umbilical cord blood bank
January 2, 2019, Montreal Gazette
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis
December 10, 2012, ASH 2012
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Umbilical cord blood: Making Every Drop Count
August 1st, 2011, McGill University Health Centre
MUHC Clinical Research Cord Blood Bank partners with the Public Cord Blood Bank of Héma-Québec
June 22nd, 2009, McGill University Health Centre
More than $19 million for sustainable genomic solutions in human health and agrifood in Québec
May 30, 2024, Génome Québec
- Michel L. Tremblay and David Langlais from McGill University in partnership with the Dr. Pierre Laneuville and Linda Peltier from the Cellular Therapy Laboratory at the McGill University Health Centre and Kanyr Pharma Inc. – Establishing therapeutic cord blood-derived NK cells for hard-to-treat cancers through omics based and pharmacological activators
The Canadian Tyrosine Kinase Inhibitor Discontinuation Trial with Imatinib Discontinuation As a First Attempt and with Dasatinib Discontinuation As a Second Attempt of Treatment-Free Remission: Results of 4 Years of Follow-up
November 13, 2019, ASH2019
Thrilled parents of MUHC’s first baby of 2019 boost umbilical cord blood bank
January 2, 2019, Montreal Gazette
When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
March 8, 2018, Current Treatment Options in Oncology
Stopping second-generation TKIs in CML
February 16, 2017, Journal Blood
High Risk of Error in Categorizing Treatment Response in Individual CML Patients by Standard Cytogenetic Analysis or PCR Assay with High CV: A Bayesian Analysis
December 10, 2012, ASH 2012
Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: Management and outcomes
June 2011, 2011 ASCO Annual Meeting
Umbilical cord blood: Making Every Drop Count
August 1st, 2011, McGill University Health Centre
MUHC Clinical Research Cord Blood Bank partners with the Public Cord Blood Bank of Héma-Québec
June 22nd, 2009, McGill University Health Centre
